Cas:156474-22-5 threo-N-Boc-D-phenylalanine epoxide manufacturer & supplier

Chemical Name:threo-N-Boc-D-phenylalanine epoxide

CAS.NO:156474-22-5

Synonyms:(2S,3R)-3-phenylproline;trans-3-phenyl-l-proline;(2S)-[1′(R)-Boc-amino-2′-phenylethyl]oxirane;Carbamic acid, N-[(1R)-1-[(2S)-oxiranyl]-2-phenylethyl]-, 1,1-dimethylethyl ester;(2S,3R)-(+)-3-Phenylpyrrolidone-2-carboxylic acid;(2S)-3-phenylpyrrolidine-2-carboxylic acid;tert-butyl [(2R,3S)]-(-)-(1-oxiranyl-2-phenylethyl)carbamate;trans-3-phenyl-(S)-proline;3-Phenyl-D-proline;(2S,3R)-3-tert-butoxycarbonylamino-1,2-epoxy-4-phenylbutane;2-Methyl-2-propanyl {(1R)-1-[(2S)-2-oxiranyl]-2-phenylethyl}carbamate;3-Phenyl-L-Proline;(2S,3R)-3-phenyl-pyrrolidine-2-carboxylic acid

Molecular Formula:C₁₅H₂₁NO₃

Molecular Weight:263.332

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:398.8±25.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.533

PSA:54.35000

Exact Mass:263.152130

LogP:3.44

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (2S,3R)-3-phenylproline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(2S,3R)-3-phenyl-pyrrolidine-2-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,trans-3-phenyl-l-proline Use and application,(2S,3R)-3-phenyl-pyrrolidine-2-carboxylic acid technical grade,usp/ep/jp grade.

Related News: The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented. threo-N-Boc-D-phenylalanine epoxide manufacturer Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. threo-N-Boc-D-phenylalanine epoxide supplier ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� threo-N-Boc-D-phenylalanine epoxide vendor ��With early evidence of clinical activity for our off-the-shelf, iPSC-derived NK cell programs, we are excited to lead in bringing next-generation CAR T-cell therapies to patients and plan to submit an IND for FT819 in the first half of 2020.�� threo-N-Boc-D-phenylalanine epoxide factory What’s more, also at the EHA meeting, BeiGene’s Brukinsa showed it could outperform Imbruvica at triggering tumor responses while causing fewer cases of atrial fibrillation, a potentially dangerous heart side effect, in its own head-to-head phase 3 study in previously treated CLL.